InvestorsHub Logo

Amatuer17

12/13/17 6:51 AM

#134095 RE: XenaLives #133161

here is clear evidence what co has done or not. So with biotechs - if co did not issue PR or told in cc - one cannot assume that the milestone happened.

Both trial starts are quarters away - M reiterated start of 3 trials in 2017 - none of them started - he did not give any explanation of this inordinate delay and no one said a word or held him responsible.

So he now has free pass to delay all milestones as he knows barking digs do not bite
———-

“AD - We are currently in the process of making the necessary regulatory submissions for the Phase 2/3 trial, which we expect will be completed within the upcoming quarter.”

Trial to be done in US and AUS - so no small trial

“The company is planning to file an upcoming clinical trial application, CTA with European regulatory authorities to conduct a Phase 2 trial for ANAVEX 2-73 in Parkinson’s disease in the randomized double-blind placebo controlled study.”


Anavex's (AVXL) CEO Christopher Missling on Q4 2017 Results - Earnings Call (Transcript) $AVXLhttp://www.seekingalpha.com/article/4131337